Centessa Pharmaceuticals (Centessa Pharmaceuticals) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 23, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Centessa Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Centessa Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Centessa Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centessa Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Centessa Pharmaceuticals (NAS:CNTA) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Centessa Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Centessa Pharmaceuticals (Centessa Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (NAS:CNTA) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

260:Germany

Address

1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT

Website

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Executives

Harris Rotman	officer: SVP Regulatory Affairs	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Antoine Yver	officer: Chief Medical Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Tia L Bush	officer: Chief Quality Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Karen M. Anderson	officer: Chief People Officer	C/O MIMECAST LTD., 191 SPRING STREET, LEXINGTON MA 02421
David J Grainger	officer: Chief Innovation Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Gregory M Weinhoff	officer: Chief Financial Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Thomas Templeman	officer: Chief Technology Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
David M Chao	officer: Chief Administrative Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Iqbal J Hussain	officer: General Counsel	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Mathias Hukkelhoven	director	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Saurabh Saha	director, officer: Chief Executive Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Javad Shahidi	officer: Chief Medical Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Medicxi Ventures Management (jersey) Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Rubertis Francesco De	director	C/O MEDICXI, COURS DE RIVE 10, GENEVA V8 CH-1204
Aaron Kantoff	director	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH